enVVeno Medical (NVNO)
Market Price (7/28/2026): $10.33 | Market Cap: $6.8 MilSector: Health Care | Industry: Life Sciences Tools & Services
enVVeno Medical (NVNO)
Market Price (7/28/2026): $10.33Market Cap: $6.8 MilSector: Health CareIndustry: Life Sciences Tools & Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -349% Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Vascular Disease Management, and Targeted Therapies. | Weak multi-year price returns2Y Excs Rtn is -128%, 3Y Excs Rtn is -157% | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -20 Mil Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -274% High stock price volatilityVol 12M is 117% Key risksNVNO key risks include [1] repeated FDA rejection of its lead product, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -349% |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Vascular Disease Management, and Targeted Therapies. |
| Weak multi-year price returns2Y Excs Rtn is -128%, 3Y Excs Rtn is -157% |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -20 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -274% |
| High stock price volatilityVol 12M is 117% |
| Key risksNVNO key risks include [1] repeated FDA rejection of its lead product, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Updated on 7/27/2026
enVVeno Medical (NVNO) stock has gained about 5% since 3/31/2026 because of the following key factors:
1. enVVeno Medical received first-ever FDA Investigational Device Exemption (IDE) approval for its TAVVE U.S. pivotal study of the enVVe System in April 2026.
This significant company-specific milestone allows the company to proceed with a U.S. pivotal study of its non-surgical replacement venous valve for severe deep Chronic Venous Insufficiency (CVI). The company projects this addresses a large unmet clinical need for approximately 3 million U.S. patients and represents a potential multi-billion-dollar market.
2. The company reported a strong cash position and extended operating runway into fiscal Q3 2027.
As of March 31, 2026 (the end of fiscal Q1 2026), enVVeno Medical held approximately $24.9 million in cash and investments, which it expects to fund operations through multiple key milestones, including the TAVVE pivotal study, into the third quarter of 2027.
Show more
enVVeno Medical (NVNO) stock has gained about 5% since 3/31/2026 because of the following key factors:
1. enVVeno Medical received first-ever FDA Investigational Device Exemption (IDE) approval for its TAVVE U.S. pivotal study of the enVVe System in April 2026.
This significant company-specific milestone allows the company to proceed with a U.S. pivotal study of its non-surgical replacement venous valve for severe deep Chronic Venous Insufficiency (CVI). The company projects this addresses a large unmet clinical need for approximately 3 million U.S. patients and represents a potential multi-billion-dollar market.
2. The company reported a strong cash position and extended operating runway into fiscal Q3 2027.
As of March 31, 2026 (the end of fiscal Q1 2026), enVVeno Medical held approximately $24.9 million in cash and investments, which it expects to fund operations through multiple key milestones, including the TAVVE pivotal study, into the third quarter of 2027.
Show more
Updated on 7/27/2026
enVVeno Medical (NVNO) stock has gained about 5% since 3/31/2026 because of the following key factors:
1. enVVeno Medical received first-ever FDA Investigational Device Exemption (IDE) approval for its TAVVE U.S. pivotal study of the enVVe System in April 2026.
This significant company-specific milestone allows the company to proceed with a U.S. pivotal study of its non-surgical replacement venous valve for severe deep Chronic Venous Insufficiency (CVI). The company projects this addresses a large unmet clinical need for approximately 3 million U.S. patients and represents a potential multi-billion-dollar market.
2. The company reported a strong cash position and extended operating runway into fiscal Q3 2027.
As of March 31, 2026 (the end of fiscal Q1 2026), enVVeno Medical held approximately $24.9 million in cash and investments, which it expects to fund operations through multiple key milestones, including the TAVVE pivotal study, into the third quarter of 2027.
3. enVVeno Medical exceeded analyst expectations for its fiscal Q1 2026 financial results.
In May 2026, the company reported a net loss of $5.89 per basic and diluted common share for fiscal Q1 2026, which beat analysts' consensus estimates of a net loss of $8.40 per share by $2.51.
4. The company secured a transformational U.S. patent for its enVVe system in July 2026.
This patent issuance further expands enVVeno Medical's intellectual property portfolio and strengthens its competitive position in the market for replacement venous valves, building on the FDA IDE approval.
Show less
enVVeno Medical (NVNO) stock has gained about 5% since 3/31/2026 because of the following key factors:
1. enVVeno Medical received first-ever FDA Investigational Device Exemption (IDE) approval for its TAVVE U.S. pivotal study of the enVVe System in April 2026.
This significant company-specific milestone allows the company to proceed with a U.S. pivotal study of its non-surgical replacement venous valve for severe deep Chronic Venous Insufficiency (CVI). The company projects this addresses a large unmet clinical need for approximately 3 million U.S. patients and represents a potential multi-billion-dollar market.
2. The company reported a strong cash position and extended operating runway into fiscal Q3 2027.
As of March 31, 2026 (the end of fiscal Q1 2026), enVVeno Medical held approximately $24.9 million in cash and investments, which it expects to fund operations through multiple key milestones, including the TAVVE pivotal study, into the third quarter of 2027.
3. enVVeno Medical exceeded analyst expectations for its fiscal Q1 2026 financial results.
In May 2026, the company reported a net loss of $5.89 per basic and diluted common share for fiscal Q1 2026, which beat analysts' consensus estimates of a net loss of $8.40 per share by $2.51.
4. The company secured a transformational U.S. patent for its enVVe system in July 2026.
This patent issuance further expands enVVeno Medical's intellectual property portfolio and strengthens its competitive position in the market for replacement venous valves, building on the FDA IDE approval.
Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The 5.3% change in NVNO stock from 3/31/2026 to 7/27/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 3312026 | 7272026 | Change |
|---|---|---|---|
| Stock Price ($) | 10.13 | 10.67 | 5.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 1 | 1 | -5.6% |
| Cumulative Contribution | 0.0% |
Market Drivers
3/31/2026 to 7/27/2026| Return | Correlation | |
|---|---|---|
| NVNO | 5.3% | |
| Market (SPY) | 13.6% | 11.0% |
| Sector (XLV) | 11.5% | -3.8% |
Fundamental Drivers
The -5.0% change in NVNO stock from 12/31/2025 to 7/27/2026 was primarily driven by a -11.9% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 12312025 | 7272026 | Change |
|---|---|---|---|
| Stock Price ($) | 11.23 | 10.67 | -5.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 1 | 1 | -11.9% |
| Cumulative Contribution | 0.0% |
Market Drivers
12/31/2025 to 7/27/2026| Return | Correlation | |
|---|---|---|
| NVNO | -5.0% | |
| Market (SPY) | 8.7% | 12.5% |
| Sector (XLV) | 6.0% | -1.3% |
Fundamental Drivers
The -92.4% change in NVNO stock from 6/30/2025 to 7/27/2026 was primarily driven by a -11.2% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 6302025 | 7272026 | Change |
|---|---|---|---|
| Stock Price ($) | 139.65 | 10.67 | -92.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 1 | 1 | -11.2% |
| Cumulative Contribution | 0.0% |
Market Drivers
6/30/2025 to 7/27/2026| Return | Correlation | |
|---|---|---|
| NVNO | -92.4% | |
| Market (SPY) | 20.6% | 18.9% |
| Sector (XLV) | 22.8% | 3.3% |
Fundamental Drivers
The -90.1% change in NVNO stock from 6/30/2023 to 7/27/2026 was primarily driven by a -50.9% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 6302023 | 7272026 | Change |
|---|---|---|---|
| Stock Price ($) | 107.80 | 10.67 | -90.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 0 | 1 | -50.9% |
| Cumulative Contribution | 0.0% |
Market Drivers
6/30/2023 to 7/27/2026| Return | Correlation | |
|---|---|---|
| NVNO | -90.1% | |
| Market (SPY) | 72.6% | 20.7% |
| Sector (XLV) | 28.9% | 8.4% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| NVNO Return | -24% | -23% | 1% | -41% | -89% | -7% | -97% |
| Peers Return | 17% | -4% | 10% | 14% | 8% | -15% | 31% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 8% | 97% |
Monthly Win Rates [3] | |||||||
| NVNO Win Rate | 33% | 33% | 58% | 33% | 50% | 57% | |
| Peers Win Rate | 50% | 52% | 57% | 52% | 57% | 34% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 43% | |
Max Drawdowns [4] | |||||||
| NVNO Max Drawdown | -49% | -52% | -59% | -63% | -94% | -34% | |
| Peers Max Drawdown | -19% | -33% | -25% | -17% | -23% | -31% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: MDT, BSX, BDX, PEN, MMSI.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 7/27/2026 (YTD)
How Low Can It Go
| Event | NVNO | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -40.9% | -18.8% |
| % Gain to Breakeven | 69.3% | 23.1% |
| Time to Breakeven | 29 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -34.2% | -9.5% |
| % Gain to Breakeven | 52.0% | 10.5% |
| Time to Breakeven | 28 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -57.2% | -6.7% |
| % Gain to Breakeven | 133.5% | 7.1% |
| Time to Breakeven | 264 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -51.6% | -24.5% |
| % Gain to Breakeven | 106.5% | 32.4% |
| Time to Breakeven | 72 days | 427 days |
In The Past
enVVeno Medical's stock fell -40.9% during the 2025 US Tariff Shock. Such a loss loss requires a 69.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | NVNO | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -40.9% | -18.8% |
| % Gain to Breakeven | 69.3% | 23.1% |
| Time to Breakeven | 29 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -34.2% | -9.5% |
| % Gain to Breakeven | 52.0% | 10.5% |
| Time to Breakeven | 28 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -57.2% | -6.7% |
| % Gain to Breakeven | 133.5% | 7.1% |
| Time to Breakeven | 264 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -51.6% | -24.5% |
| % Gain to Breakeven | 106.5% | 32.4% |
| Time to Breakeven | 72 days | 427 days |
In The Past
enVVeno Medical's stock fell -40.9% during the 2025 US Tariff Shock. Such a loss loss requires a 69.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About enVVeno Medical (NVNO)
enVVeno Medical Corporation (NASDAQ: NVNO) is a medical device company dedicated to advancing the treatment of venous diseases through innovative bioprosthetic tissue-based solutions. The company's core focus is on developing products that enhance the standard of care for patients suffering from severe venous conditions, aiming to improve their quality of life by restoring proper venous function.
The company's lead product is the VenoValve, a surgical implant designed for the treatment of severe deep venous chronic venous insufficiency. This innovative bioprosthetic device functions as a one-way valve, which is implanted in the femoral vein. Its purpose is to help restore healthy blood flow in the leg, thereby addressing a critical unmet need for patients with compromised venous systems.
enVVeno Medical primarily targets the medical community, including vascular surgeons and other healthcare professionals who specialize in treating severe chronic venous insufficiency. The market for its solutions comprises patients worldwide who suffer from this debilitating condition, seeking to provide them with a more effective and durable treatment option.
AI Analysis | Feedback
Here are 1-2 brief analogies to describe enVVeno Medical (NVNO):
- They are like the Edwards Lifesciences of leg veins, focusing on developing replacement valves for severe venous insufficiency.
- Think of them as a specialized medical device company, similar to Inari Medical, but for implantable venous valves rather than clot removal.
AI Analysis | Feedback
- VenoValve: A surgical implant designed to act as a one-way valve in the femoral vein to help restore proper blood flow in the leg and treat severe deep venous chronic venous insufficiency.
AI Analysis | Feedback
enVVeno Medical (NVNO) is a medical device company focused on developing a surgical implant (VenoValve) for the treatment of venous diseases. As such, its products are not sold directly to individual patients. Instead, the company sells its devices to healthcare institutions and medical professionals who perform the surgical procedures.
The major customers for enVVeno Medical would primarily consist of the following categories of healthcare providers:
- Hospitals: These are major purchasers of medical devices and surgical implants for their operating rooms, surgical departments, and specialized units (e.g., vascular surgery).
- Surgical Centers (Ambulatory Surgical Centers - ASCs): Facilities that specialize in outpatient surgical procedures, which would acquire devices like the VenoValve for specific interventions they perform.
- Vascular Clinics and Specialists: Medical practices and specialist groups focused on treating vascular diseases, who would purchase and utilize the VenoValve as part of their patient care and treatment protocols.
These entities are not typically public companies with individual stock symbols but rather medical institutions and professional practices that integrate the VenoValve into their surgical and treatment offerings.
AI Analysis | Feedback
null
AI Analysis | Feedback
Robert Berman, Chief Executive Officer, Director
Mr. Berman has served as Chief Executive Officer and a member of enVVeno Medical's Board of Directors since April 2018. He has over 25 years of experience in various areas including healthcare, finance, acquisitions, marketing, compliance, turnarounds, and the development and licensing of emerging technologies. From September 2012 until July 2017, Mr. Berman served as the President, Chief Executive Officer, and a board member of ITUS Corporation (now Anixa Biosciences), successfully transitioning it from a developer of flat panel display technologies to a Nasdaq-listed cancer therapeutics company. He began his career at the law firm Blank Rome.
Jennifer Bright, Chief Financial Officer
Ms. Bright joined enVVeno Medical as Chief Financial Officer in May 2025. She brings over 25 years of financial and strategic leadership experience gained across several commercial-stage medical device and pharmaceutical companies, including Biolase, Spectrum Pharmaceuticals, Apria Healthcare, Smile Brands, and Teleflex Medical. Ms. Bright also has technical accounting and auditing experience from her time at PricewaterhouseCoopers LLP and is a Certified Public Accountant. She previously held the CFO role at BIOLASE, Inc.
Marc H. Glickman, M.D., Senior Vice President and Chief Medical Officer
Dr. Glickman has served as Senior Vice President and Chief Medical Officer since May 2016. He started a vascular practice in Norfolk, Virginia in 1981, where he established the first Vein Center in Virginia and created a dialysis access center. Prior to joining enVVeno Medical, he was employed by Sentara Health Care as director of Vascular Services until his retirement in 2014. Dr. Glickman is board certified in Vascular Surgery and is a past president of the Vascular Society of the Americas. He has also served on the advisory boards for several medical companies.
Hamed Alavi, Ph. D., Senior Vice President and Chief Technology Officer
Dr. Alavi is an innovative leader with a strong track record in developing advanced medical device technologies in both startup and large corporate environments. His work includes pioneering efforts in hybrid tissue and implantable medical devices.
Kevin Belteau, Senior Vice President, Clinical and Regulatory Affairs
Mr. Belteau joined enVVeno Medical in August 2022, following a twenty-three-year career in clinical operations at Medtronic. He started as a field engineer at Medtronic and advanced through various clinical operations roles, managing his own team of professionals. He has been directly involved in over 75 clinical studies for Class III medical devices seeking PMA approval.AI Analysis | Feedback
The key risks to enVVeno Medical (NVNO) are primarily centered around regulatory challenges and the associated financial implications.
Key Risks to enVVeno Medical (NVNO)
- Regulatory Approval and Clinical Trial Success: The most significant risk for enVVeno Medical stems from its ability to secure regulatory approval for its medical devices. The U.S. FDA denied premarket approval (PMA) for the company's lead product, VenoValve, citing insufficient assurance of safety and efficacy. The FDA's decision was based on concerns regarding the clinical improvement data's ability to establish a favorable benefit-risk profile, a lack of specific hemodynamic measurements correlating with patient improvement, and safety issues related to the surgical procedure requiring re-hospitalizations. While enVVeno Medical has shifted its focus to its next-generation enVVe valve, this product is still in development and requires successful human testing and alignment with the FDA on achievable endpoints, presenting ongoing regulatory and clinical trial risks.
- Financial Sustainability and Cash Burn: The regulatory setback for VenoValve has directly impacted enVVeno Medical's path to commercialization and revenue generation. The company currently reports zero revenue. Despite a robust cash position that is expected to fund operations into the second quarter of 2027, enVVeno Medical has a significant cash burn rate of $4–5 million per quarter. Continued delays in bringing a product to market due to regulatory hurdles will further deplete its cash reserves, potentially necessitating additional capital raises, which could be dilutive to existing shareholders.
AI Analysis | Feedback
null
AI Analysis | Feedback
enVVeno Medical (NASDAQ: NVNO) focuses on developing bioprosthetic tissue-based solutions for venous diseases, with its primary product being the VenoValve. The addressable market for the VenoValve is substantial within the United States.
The total addressable market for enVVeno Medical's VenoValve, which is designed to treat severe deep venous chronic venous insufficiency (CVI), consists of approximately 2.5 million patients in the U.S.. Some estimates also place this patient population between 2.5 million and 3.5 million in the U.S., specifically for those with severe deep venous CVI who currently lack effective treatment options.
Annually, there are about 600,000 new patients in the U.S. who could potentially benefit from the VenoValve. With an expected product pricing between $20,000 and $25,000 per device, the potential market value for treating these 2.5 million U.S. patients could range from $50 billion to $62.5 billion. Furthermore, a study indicated that the VenoValve could potentially save $5.9 billion annually in healthcare costs for these approximately 2.5 million U.S. patients with severe CVI.
AI Analysis | Feedback
enVVeno Medical Corporation (NASDAQ: NVNO) is currently a late clinical-stage medical device company with no reported product revenue, focusing on the development of bioprosthetic solutions for venous diseases. The company's future revenue growth over the next 2-3 years is primarily anticipated to be driven by the following factors:
- FDA Approval and Commercialization of enVVe: Following an unfavorable FDA appeal decision regarding its VenoValve product in November 2025, enVVeno Medical's future outlook significantly relies on the success of its next-generation, non-surgical enVVe transcatheter venous valve. The company completed a six-month pre-clinical GLP study for enVVe and aims to file an Investigational Device Exemption (IDE) seeking FDA approval for its pivotal trial by mid-2025. Successful completion of clinical trials and subsequent FDA Premarket Approval (PMA) would enable the commercialization of enVVe, introducing the company's first revenue-generating product.
- Market Penetration within the Deep Venous Chronic Venous Insufficiency (CVI) Market: The enVVe device is designed to treat severe deep venous CVI, addressing a substantial and underserved patient population. The total addressable market for similar venous valve replacement solutions is estimated at approximately 2.5 million patients in the U.S. alone, with about 600,000 new patients annually. Achieving regulatory approval and effectively penetrating this large market segment with enVVe would be a significant driver of future revenue growth for enVVeno Medical.
- Adoption Driven by enVVe's Minimally Invasive Nature: As a non-surgical, transcatheter-based replacement venous valve, enVVe offers a less invasive treatment option compared to traditional surgical procedures. This characteristic could lead to broader acceptance among healthcare professionals and patients, potentially accelerating market adoption and revenue growth upon its commercial launch.
AI Analysis | Feedback
Share Issuance
- The number of shares outstanding for enVVeno Medical significantly increased from 9.18 million in 2021 to 20.155 million by September 2025.
- EnVVeno Medical executed a one-for-thirty-five reverse stock split on January 20, 2026, which reduced the common shares outstanding from 22,946,223 to 655,606.
- Shareholders have experienced substantial dilution in the past year, as of March 2026.
Inbound Investments
- EnVVeno Medical announced a private placement of $28 million on July 31, 2023.
- The company has raised a total of $874K across six funding rounds, including four Post-IPO rounds and two unattributed rounds, with the largest being a Post-IPO round on October 6, 2023.
- Institutional investors collectively hold 6,577,869 shares, with major holders including Perceptive Advisors Llc, Vanguard Group Inc., and Nantahala Capital Management LLC.
Capital Expenditures
- EnVVeno Medical reported $0 in capital expenditures during Q3 2025, marking a 100% decrease from the preceding quarter.
- The company primarily allocates its capital to research and development (R&D), with these expenses totaling $2.6 million in Q3 2025.
- The majority of the company's costs are focused on R&D and general administrative expenses, rather than Cost of Goods Sold.
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 80.16 |
| Mkt Cap | 28.6 |
| Rev LTM | 11,079 |
| Op Inc LTM | 1,640 |
| FCF LTM | 1,637 |
| FCF 3Y Avg | 1,350 |
| CFO LTM | 2,064 |
| CFO 3Y Avg | 1,887 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 11.1% |
| Rev Chg 3Y Avg | 9.6% |
| Rev Chg Q | 9.9% |
| QoQ Delta Rev Chg LTM | 2.5% |
| Op Inc Chg LTM | 18.9% |
| Op Inc Chg 3Y Avg | 14.4% |
| Op Mgn LTM | 14.5% |
| Op Mgn 3Y Avg | 13.2% |
| QoQ Delta Op Mgn LTM | 0.1% |
| CFO/Rev LTM | 19.3% |
| CFO/Rev 3Y Avg | 17.8% |
| FCF/Rev LTM | 14.6% |
| FCF/Rev 3Y Avg | 14.0% |
Segment Financials
Revenue by Segment| $ Mil | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|
| Royalty income | 0 | 0 | 0 | 0 |
| Contract research - related party | 0 | 0 | ||
| Product sales | 0 | 1 | ||
| Total | 0 | 0 | 0 | 1 |
| $ Mil | 2025 | 2024 |
|---|---|---|
| Medical Device development | -21 | |
| Single Segment | -24 | |
| Total | -21 | -24 |
| $ Mil | 2025 | 2024 |
|---|---|---|
| Medical Device development | -19 | |
| Single Segment | -22 | |
| Total | -19 | -22 |
| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Medical Device development | 45 | ||||
| Single Segment | 49 | 42 | 58 | 11 | |
| Total | 45 | 49 | 42 | 58 | 11 |
Price Behavior
Price Behavior
| Market Price | $10.67 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 05/31/2018 | |
| Distance from 52W High | -94.1% | |
| 50 Days | 200 Days | |
| DMA Price | $10.61 | $13.26 |
| DMA Trend | down | down |
| Distance from DMA | 0.6% | -19.5% |
| 3M | 1YR | |
| Volatility | 65.4% | 117.8% |
| Downside Capture | 29.66 | 436.20 |
| Upside Capture | -28.10 | 24.33 |
| Correlation (SPY) | 8.1% | 17.4% |
NVNO Betas & Captures as of 6/30/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.59 | 0.82 | 0.63 | 0.92 | 1.90 | 1.28 |
| Up Beta | 1.37 | 0.78 | 1.12 | 1.36 | 1.51 | 1.06 |
| Down Beta | 5.43 | 3.46 | 2.42 | 2.78 | 1.57 | 1.29 |
| Up Capture | -146% | -1% | 2% | -1% | 57% | 77% |
| Bmk +ve Days | 11 | 24 | 40 | 67 | 140 | 429 |
| Stock +ve Days | 7 | 18 | 30 | 60 | 121 | 357 |
| Down Capture | -90% | -24% | -36% | 23% | 200% | 112% |
| Bmk -ve Days | 10 | 17 | 23 | 58 | 112 | 321 |
| Stock -ve Days | 12 | 21 | 28 | 59 | 124 | 374 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with NVNO | |
|---|---|---|---|---|
| NVNO | -93.8% | 117.9% | -1.56 | - |
| Sector ETF (XLV) | 22.0% | 15.7% | 1.07 | 3.7% |
| Equity (SPY) | 17.6% | 12.7% | 1.00 | 17.7% |
| Gold (GLD) | 20.8% | 28.1% | 0.66 | 1.0% |
| Commodities (DBC) | 29.6% | 19.5% | 1.21 | -2.7% |
| Real Estate (VNQ) | 13.9% | 14.1% | 0.69 | 6.2% |
| Bitcoin (BTCUSD) | -46.0% | 43.0% | -1.31 | 16.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with NVNO | |
|---|---|---|---|---|
| NVNO | -44.0% | 81.8% | -0.27 | - |
| Sector ETF (XLV) | 6.8% | 15.0% | 0.27 | 12.4% |
| Equity (SPY) | 13.2% | 17.1% | 0.59 | 22.0% |
| Gold (GLD) | 17.2% | 18.4% | 0.75 | 2.8% |
| Commodities (DBC) | 9.7% | 19.5% | 0.38 | 1.1% |
| Real Estate (VNQ) | 3.3% | 18.9% | 0.07 | 15.7% |
| Bitcoin (BTCUSD) | 15.8% | 53.5% | 0.47 | 15.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with NVNO | |
|---|---|---|---|---|
| NVNO | -45.3% | 93.4% | -0.33 | - |
| Sector ETF (XLV) | 10.1% | 16.6% | 0.49 | 14.4% |
| Equity (SPY) | 14.9% | 17.9% | 0.71 | 20.2% |
| Gold (GLD) | 11.4% | 16.1% | 0.58 | 1.4% |
| Commodities (DBC) | 6.9% | 18.0% | 0.30 | 4.7% |
| Real Estate (VNQ) | 5.2% | 20.7% | 0.21 | 16.5% |
| Bitcoin (BTCUSD) | 58.0% | 66.2% | 0.98 | 10.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/06/2026 | 10-Q |
| 12/31/2025 | 03/26/2026 | 10-K |
| 09/30/2025 | 10/30/2025 | 10-Q |
| 06/30/2025 | 07/31/2025 | 10-Q |
| 03/31/2025 | 04/30/2025 | 10-Q |
| 12/31/2024 | 02/28/2025 | 10-K |
| 09/30/2024 | 10/31/2024 | 10-Q |
| 06/30/2024 | 07/31/2024 | 10-Q |
| 03/31/2024 | 05/08/2024 | 10-Q |
| 12/31/2023 | 02/29/2024 | 10-K |
| 09/30/2023 | 10/26/2023 | 10-Q |
| 06/30/2023 | 07/31/2023 | 10-Q |
| 03/31/2023 | 04/28/2023 | 10-Q |
| 12/31/2022 | 03/02/2023 | 10-K |
| 09/30/2022 | 10/27/2022 | 10-Q |
| 06/30/2022 | 08/03/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/06/2026 | 10-Q |
| 12/31/2025 | 03/26/2026 | 10-K |
| 09/30/2025 | 10/30/2025 | 10-Q |
| 06/30/2025 | 07/31/2025 | 10-Q |
| 03/31/2025 | 04/30/2025 | 10-Q |
| 12/31/2024 | 02/28/2025 | 10-K |
| 09/30/2024 | 10/31/2024 | 10-Q |
| 06/30/2024 | 07/31/2024 | 10-Q |
| 03/31/2024 | 05/08/2024 | 10-Q |
| 12/31/2023 | 02/29/2024 | 10-K |
| 09/30/2023 | 10/26/2023 | 10-Q |
| 06/30/2023 | 07/31/2023 | 10-Q |
| 03/31/2023 | 04/28/2023 | 10-Q |
| 12/31/2022 | 03/02/2023 | 10-K |
| 09/30/2022 | 10/27/2022 | 10-Q |
| 06/30/2022 | 08/03/2022 | 10-Q |
| 03/31/2022 | 04/29/2022 | 10-Q |
| 12/31/2021 | 03/28/2022 | 10-K |
| 09/30/2021 | 11/12/2021 | 10-Q |
| 06/30/2021 | 08/11/2021 | 10-Q |
| 03/31/2021 | 05/12/2021 | 10-Q |
| 12/31/2020 | 03/31/2021 | 10-K |
| 09/30/2020 | 11/17/2020 | 10-Q |
| 06/30/2020 | 08/14/2020 | 10-Q |
| 03/31/2020 | 06/08/2020 | 10-Q |
| 12/31/2019 | 03/18/2020 | 10-K |
| 09/30/2019 | 10/31/2019 | 10-Q |
| 06/30/2019 | 08/05/2019 | 10-Q |
Insider Activity
Updated 6/12/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Duhay, Francis | Direct | Sell | 6122026 | 10.30 | 140 | 1,443 | 24,340 | Form | |
| 2 | Duhay, Francis | Direct | Sell | 3132026 | 11.52 | 140 | 1,613 | 28,829 | Form | |
| 3 | Duhay, Francis | Direct | Sell | 12122025 | 0.36 | 4,900 | 1,742 | 32,909 | Form | |
| 4 | Duhay, Francis | Direct | Sell | 9172025 | 0.83 | 4,900 | 4,067 | 80,879 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Duhay, Francis | Direct | Sell | 6122026 | 10.30 | 140 | 1,443 | 24,340 | Form | |
| 2 | Duhay, Francis | Direct | Sell | 3132026 | 11.52 | 140 | 1,613 | 28,829 | Form | |
| 3 | Duhay, Francis | Direct | Sell | 12122025 | 0.36 | 4,900 | 1,742 | 32,909 | Form | |
| 4 | Duhay, Francis | Direct | Sell | 9172025 | 0.83 | 4,900 | 4,067 | 80,879 | Form |
Industry Resources
| Health Care Resources |
| U.S. National Library of Medicine |
| ClinicalTrials.gov |
| Modern Healthcare |
| Healthcare Dive |
| Fierce Healthcare |
| Health Affairs |
| Health Data Management |
| FDA Tracker |
| Life Sciences Tools & Services Resources |
| GenomeWeb |
| BioSpace |
| The Scientist |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 7/27/2026